{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-24-000013","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.800719+00:00","generated_at":"2026-06-06T08:08:42.703598+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Inspire Medical Q4 revenue $192.5M (+40%), first net income quarter $14.8M","bullets":["Q4 revenue $192.5M (+40% YoY); full year $624.8M (+53%). U.S. revenue $189.4M (+41%).","Q4 net income $14.8M (diluted EPS $0.49) vs $3.2M ($0.10) a year ago; FY net loss improved 53% to $21.2M.","Gross margin 85.4% in Q4 vs 83.9% a year ago; FY 2024 guidance 83%-85%.","Reaffirms FY 2024 revenue guidance of $775M-$785M (24-26% growth).","Added 78 new U.S. implanting centers in Q4 (total 1,180) and 13 sales territories (total 287)."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-24-000013","json":"https://secwatch.observer/filing/0001609550-24-000013.json","markdown":"https://secwatch.observer/filing/0001609550-24-000013.md","text":"https://secwatch.observer/filing/0001609550-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000013/0001609550-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000013/insp-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:08:42.703598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e0c961ef81dfd3369e5c13b5197496f3feedc2d","claim":"Inspire Medical Systems, Inc. reported the quarter and year ended December 31, 2023 results: revenue $192.5 million, net income $14.8 million, EPS $0.49. Guidance reaffirmed.","evidence_excerpt":"sleep apnea, today reported financial results for the quarter and year ended December 31, 2023. Recent Business Highlights and Full Year 2024 Guidance • Generated revenue of $192.5 million in the fourth quarter of 2023, a 40% increase over the same quarter last year, and revenue of $624.8 million in full year 2023, a 53% increase over full year 2022 • Achieved","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000013/0001609550-24-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$192.5 million"},{"label":"Net income","value":"$14.8 million"},{"label":"EPS","value":"$0.49"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}